Pyxis Oncology is in good handsIt’s been a nice month for Pyxis Oncology: After penning a major licensing deal with Pfizer, the startup now has $152 million extra in the bank to help it push on with its expanded pipeline.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.30 USD
−77.33 M USD
16.15 M USD
43.77 M
About Pyxis Oncology, Inc.
Sector
Industry
CEO
Lara S. Sullivan
Website
Headquarters
Boston
Founded
2018
FIGI
BBG00PQFFCV5
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where PYXS is featured.
Related stocks
Frequently Asked Questions
The current price of PYXS is 1.06 USD — it has decreased by −2.75% in the past 24 hours. Watch Pyxis Oncology, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Pyxis Oncology, Inc. stocks are traded under the ticker PYXS.
PYXS stock has risen by 13.22% compared to the previous week, the month change is a −7.02% fall, over the last year Pyxis Oncology, Inc. has showed a −75.69% decrease.
We've gathered analysts' opinions on Pyxis Oncology, Inc. future price: according to them, PYXS price has a max estimate of 8.00 USD and a min estimate of 5.00 USD. Watch PYXS chart and read a more detailed Pyxis Oncology, Inc. stock forecast: see what analysts think of Pyxis Oncology, Inc. and suggest that you do with its stocks.
PYXS reached its all-time high on Oct 8, 2021 with the price of 19.00 USD, and its all-time low was 0.83 USD and was reached on Apr 7, 2025. View more price dynamics on PYXS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PYXS stock is 5.83% volatile and has beta coefficient of 1.09. Track Pyxis Oncology, Inc. stock price on the chart and check out the list of the most volatile stocks — is Pyxis Oncology, Inc. there?
Today Pyxis Oncology, Inc. has the market capitalization of 65.29 M, it has increased by 0.48% over the last week.
Yes, you can track Pyxis Oncology, Inc. financials in yearly and quarterly reports right on TradingView.
Pyxis Oncology, Inc. is going to release the next earnings report on May 9, 2025. Keep track of upcoming events with our Earnings Calendar.
PYXS earnings for the last quarter are −0.62 USD per share, whereas the estimation was −0.32 USD resulting in a −93.64% surprise. The estimated earnings for the next quarter are −0.29 USD per share. See more details about Pyxis Oncology, Inc. earnings.
Pyxis Oncology, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
PYXS net income for the last quarter is −35.57 M USD, while the quarter before that showed −21.20 M USD of net income which accounts for −67.76% change. Track more Pyxis Oncology, Inc. financial stats to get the full picture.
No, PYXS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 28, 2025, the company has 44 employees. See our rating of the largest employees — is Pyxis Oncology, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Pyxis Oncology, Inc. EBITDA is −65.51 M USD, and current EBITDA margin is −405.76%. See more stats in Pyxis Oncology, Inc. financial statements.
Like other stocks, PYXS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Pyxis Oncology, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Pyxis Oncology, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Pyxis Oncology, Inc. stock shows the sell signal. See more of Pyxis Oncology, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.